NCT06851559

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Phathom Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
DRUG	Vonoprazan	Vonoprazan will be administered orally as a tablet
DRUG	Placebo	Placebo will be administered orally as tablet

Timeline

• Start date: 2025-10-30
• Primary completion: 2026-12-01
• Completion: 2027-03-01
• First posted: 2025-02-28
• Last updated: 2026-02-24

Locations

39 sites across 1 country: United States

Regulatory

• FDA-regulated drug study